Related Experiment Video

Updated: Aug 9, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Simvastatin treatment improves endothelial function and increases fibrinolysis in patients with hypercholestrolemia

Gulay S Guven1, Enver Atalar, Bunyamin Yavuz

  • 1Hacettepe University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey.

Journal of the National Medical Association
|April 21, 2006
PubMed

Insights

Simvastatin treatment significantly lowered cholesterol and decreased thrombin activatable fibrinolysis inhibitor (TAFI) levels in hyperlipidemic patients. This study also demonstrated simvastatin

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Biochemistry

Background:

  • Statins offer cardiovascular benefits beyond lipid reduction.
  • Thrombin activatable fibrinolysis inhibitor (TAFI) is a risk factor for thrombosis.
  • Endothelial dysfunction predicts cardiovascular events.

Purpose of the Study:

  • To evaluate simvastatin's impact on circulating TAFI levels.
  • To assess simvastatin's effect on endothelial function in hypercholesterolemia.
  • To explore non-lipid-related mechanisms of statin action.

Main Methods:

  • 35 hyperlipidemic patients received 40 mg daily simvastatin for 8 weeks.
  • Endothelial function assessed via brachial artery flow-mediated dilation (FMD).
  • Plasma lipids, TAFI levels, and FMD measured pre- and post-treatment.

Main Results:

  • Simvastatin significantly reduced total cholesterol, LDL, and triglycerides (p<0.05).
  • Plasma TAFI levels decreased significantly post-treatment (p<0.001).
  • Mean FMD improved significantly from 7.7% to 13.0% (p=0.001).

Conclusions:

  • Decreased TAFI suggests simvastatin benefits fibrinolysis.
  • Improved endothelial function indicates potential for reduced cardiovascular events.
  • Simvastatin demonstrates pleiotropic effects in hyperlipidemic patients.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...